Goldman Sachs Group Inc. Has $5.16 Million Position in Repligen Corporation (RGEN)
Goldman Sachs Group Inc. decreased its position in Repligen Corporation (NASDAQ:RGEN) by 10.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 146,676 shares of the biotechnology company’s stock after selling 16,211 shares during the period. Goldman Sachs Group Inc. owned 0.43% of Repligen Corporation worth $5,163,000 as of its most recent SEC filing.
A number of other large investors have also recently added to or reduced their stakes in RGEN. Envestnet Asset Management Inc. increased its stake in Repligen Corporation by 3.6% in the fourth quarter. Envestnet Asset Management Inc. now owns 6,388 shares of the biotechnology company’s stock worth $197,000 after buying an additional 223 shares during the period. Thrivent Financial for Lutherans boosted its position in shares of Repligen Corporation by 4.6% in the fourth quarter. Thrivent Financial for Lutherans now owns 18,070 shares of the biotechnology company’s stock worth $557,000 after buying an additional 800 shares in the last quarter. Norges Bank acquired a new position in shares of Repligen Corporation during the fourth quarter worth approximately $8,527,000. Teachers Advisors LLC boosted its position in shares of Repligen Corporation by 11.4% in the fourth quarter. Teachers Advisors LLC now owns 56,695 shares of the biotechnology company’s stock worth $1,747,000 after buying an additional 5,819 shares in the last quarter. Finally, Macquarie Group Ltd. boosted its position in shares of Repligen Corporation by 481.1% in the fourth quarter. Macquarie Group Ltd. now owns 319,668 shares of the biotechnology company’s stock worth $9,852,000 after buying an additional 264,659 shares in the last quarter. 99.49% of the stock is currently owned by institutional investors and hedge funds.
Repligen Corporation (NASDAQ:RGEN) traded up 1.26% on Friday, reaching $40.21. 266,076 shares of the company traded hands. Repligen Corporation has a 52-week low of $26.16 and a 52-week high of $46.81. The stock has a 50-day moving average of $41.56 and a 200 day moving average of $37.05. The company has a market capitalization of $1.50 billion, a PE ratio of 78.69 and a beta of 1.30.
Repligen Corporation (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported $0.20 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.15 by $0.05. The business had revenue of $32.40 million during the quarter, compared to the consensus estimate of $31.72 million. Repligen Corporation had a net margin of 15.61% and a return on equity of 9.90%. The firm’s revenue was up 11.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.16 EPS. On average, equities analysts forecast that Repligen Corporation will post $0.59 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This article was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/08/19/repligen-corporation-rgen-stake-cut-by-goldman-sachs-group-inc-updated-updated-updated.html.
A number of research analysts have commented on RGEN shares. Zacks Investment Research upgraded shares of Repligen Corporation from a “hold” rating to a “buy” rating and set a $46.00 price target for the company in a research note on Saturday, August 12th. BidaskClub cut shares of Repligen Corporation from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. First Analysis restated an “equal weight” rating and set a $40.00 price target on shares of Repligen Corporation in a research note on Friday, April 21st. Jefferies Group LLC reiterated a “hold” rating and issued a $40.00 target price (up previously from $33.00) on shares of Repligen Corporation in a research note on Wednesday, June 28th. Finally, William Blair initiated coverage on shares of Repligen Corporation in a research note on Friday, July 21st. They issued an “outperform” rating for the company. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Repligen Corporation has a consensus rating of “Buy” and an average target price of $42.00.
About Repligen Corporation
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Receive News & Stock Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related stocks with our FREE daily email newsletter.